Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Market Closed 09-04 16:00:00 EDT

1.16

-0.54

-31.76%

盘后1.19

+0.03+2.59%

19:59 EDT

High1.56	Low1.16	Vol15.51M
Open1.50	D1 Closing1.70	Amplitude23.24%
Mkt Cap1.72M	Tradable Cap1.71M	Total Shares1.49M
T/O28.92M	T/O Rate1,051.01%	Tradable Shares1.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":1.16,"timestamp":1788552000000,"preClose":1.7,"halted":0,"volume":15512447,"hourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.16,"latestTime":"19:59 EDT","volume":302367,"amount":365529.2841,"timestamp":1788566394845,"change":0.03,"changeRate":0.025862,"amplitude":0.137931},"delay":0,"changeRate":-0.31764705882352945,"floatShares":1475956,"shares":1485551,"eps":-175.92,"marketStatus":"Market Closed","change":-0.54,"latestTime":"09-04 16:00:00 EDT","open":1.495,"high":1.555,"low":1.16,"amount":28921966.1861367,"amplitude":0.232353,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-175.92,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":1.7,"preHourTrading":{"tag":"盘前","latestPrice":1.5,"preClose":1.7,"latestTime":"09:29 EDT","volume":7111987,"amount":14124734.044600701,"timestamp":1788528599442,"change":-0.2,"changeRate":-0.117647,"amplitude":0.494118},"postHourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.16,"latestTime":"19:59 EDT","volume":302367,"amount":365529.2841,"timestamp":1788566394845,"change":0.03,"changeRate":0.025862,"amplitude":0.137931},"volumeRatio":72.31788647599103},"requestUrl":"/m/hq/s/CMND/tweets","defaultTab":"tweets","newsList":[{"id":"2664339136","title":"Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339136?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:32","pubTimestamp":1788521539,"startTime":"0","endTime":"0","summary":"Clearmind Medicine agrees to buy 51% of Charging Robotics for $2.5 millionClearmind Medicine agreed to buy 51% of Charging Robotics for USD 2.5 million.Deal includes a USD 1.5 million loan to Charging","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL97C896:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BN0W2W23.USD","CHEV","LU2095319765.USD","BK4585","BK4588","LU2210150020.SGD","IE00BQXX3F31.USD","SG9999014005.SGD","LU2210149790.SGD","LU0314104364.USD","BK4124","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BCDF","NDAQ","IE00BQXX3C00.GBP","IE00B64PRP62.GBP","BK4007","BK4112","IE00BQXX3D17.EUR","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","CMND","IE00BKPKM429.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664633918","title":"Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2664633918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664633918?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:32","pubTimestamp":1788521520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA6ZKRHH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339900","title":"Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339900?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:32","pubTimestamp":1788521520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA6ZKRHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664849839","title":"Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664849839","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664849839?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:03","pubTimestamp":1788379413,"startTime":"0","endTime":"0","summary":"Clearmind Medicine sets USD 1 conversion price for USD 696,079.50 in notes into common sharesClearmind set a $1 per-share conversion price for outstanding convertible notes totaling USD 696,079.50, ov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL58t3nY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855251","title":"Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855251","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855251?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:37","pubTimestamp":1788262637,"startTime":"0","endTime":"0","summary":"Clearmind Medicine starts Phase IIa CMND-100 trial in alcohol use disorder patientsClearmind Medicine launched a Phase IIa stage in its Phase I/IIa trial of CMND-100 for alcohol use disorder.Results h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL3L61qH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BQXX3C00.GBP","BK4112","IE00BQXX3D17.EUR","BK4585","IE00BQXX3F31.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4007","BK4588","IE00BN0W2W23.USD","CMND","SG9999014021.USD","NDAQ","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","BCDF","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585523","title":"Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585523","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664585523?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:37","pubTimestamp":1788262620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA1SZQTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661645271","title":"SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2661645271","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661645271?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:20","pubTimestamp":1787577613,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC) announced that its subsidiary, NeuroThera Labs, and Clearmind Medicine (CMND) have published a U.S. patent application covering a n...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-clearmind-publish-u-s-patent-application-for-mdma-pea-combination-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-clearmind-publish-u-s-patent-application-for-mdma-pea-combination-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRC","CMND","BK4007","BK4139","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276551","title":"Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276551","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276551?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:04","pubTimestamp":1787573044,"startTime":"0","endTime":"0","summary":"Clearmind Medicine says US publishes MDMA-PEA patent application for PTSD treatmentClearmind reported U.S. publication of its patent application covering a combination of MDMA and N-acylethanolamines ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL7WjfCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4588","LU2210150020.SGD","BK4007","NDAQ","IE00BQXX3F31.USD","CMND","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BCDF","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276308","title":"Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276308?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:03","pubTimestamp":1787572980,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA8NJTTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159719","title":"Clearmind Advances CMND-100 into Alcohol Use Disorder Patients After Phase I/II Safety Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159719","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159719?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:36","pubTimestamp":1786621015,"startTime":"0","endTime":"0","summary":"Clearmind advances CMND-100 into alcohol use disorder patients after Phase I/II safety milestoneClearmind Medicine advanced its FDA-regulated Phase I/II trial of CMND-100 into patient testing for alco","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL4DqCzx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","BCDF","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4007","CMND","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659760159","title":"Clearmind Advances Cmnd-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2659760159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659760159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:36","pubTimestamp":1786620973,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658191367","title":"Clearmind Medicine Announces Positive Permeation Results for Intranasal Meai Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2658191367","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658191367?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:06","pubTimestamp":1786453564,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Announces Positive Permeation Results For Intranasal Meai FormulationAug 11 (Reuters)-Clearmind Medicine IncCMND.O:CLEARMIND MEDICINE ANNOUNCES POSITIVE PERMEATION RESULTS FOR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUABBCJJM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658918974","title":"Clearmind Medicine reports MEAI development program permeation study results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658918974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658918974?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:36","pubTimestamp":1786451769,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced permeation study results from its ongoing intranasal MEAI development program. The new findings confirm that th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-reports-meai-development-program-permeation-study-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-reports-meai-development-program-permeation-study-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658699066","title":"Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2658699066","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658699066?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:06","pubTimestamp":1786450017,"startTime":"0","endTime":"0","summary":"Clearmind Medicine reports positive permeation results for intranasal MEAI formulation studyClearmind Medicine reported new permeation study results for its intranasal MEAI program, with findings alre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL9QLcrW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","BK4007","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","IE00BN0W2W23.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BCDF","BK4112","CMND","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990636","title":"Clearmind Medicine - Intranasal Meai Shows Enhanced Nasal Retention Without Compromising Permeation","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990636?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:05","pubTimestamp":1786449900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUABBCJJM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657248637","title":"Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study","url":"https://stock-news.laohu8.com/highlight/detail?id=2657248637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657248637?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:51","pubTimestamp":1786024289,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that its independent DSMB has unanimously approved advancing the Company’s ongoing FDA-regulated Phase I/II cli...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-reports-dsmb-approves-advancing-phase-i-ii-aud-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-reports-dsmb-approves-advancing-phase-i-ii-aud-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND","LABU","BK4585","CROC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667632","title":"Clearmind Advances CMND-100 Alcohol Use Disorder Trial into Patient Testing After Phase I Safety Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667632","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657667632?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:26","pubTimestamp":1786022817,"startTime":"0","endTime":"0","summary":"Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readoutClearmind Medicine’s DSMB cleared its FDA-regulated Phase I/II trial of CMND-100 to move into Pa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3wlnH2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636936","title":"Clearmind Reaches Key Clinical Trial Milestone as Dsmb Unanimously Clears Progression in AUD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636936?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA555HVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656376261","title":"Clearmind Signs LOI to Buy 51% Stake in EV Wireless Charging Firm for $2.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376261","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376261?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:06","pubTimestamp":1785758816,"startTime":"0","endTime":"0","summary":"Clearmind signs LOI to buy 51% stake in EV wireless charging firm for $2.5 millionClearmind Medicine entered a non-binding LOI to buy 51% of an EV wireless charging solutions company focused on automa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL8fJd1j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","BCDF","BK4588","LU2095319765.USD","SG9999014021.USD","CMND","BK4007","SG9999014005.SGD","IE00BN0W2W23.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656376945","title":"Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376945?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:02","pubTimestamp":1785758520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA2R9NG7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":-0.3409},{"period":"1month","weight":-0.3409},{"period":"3month","weight":-0.7085},{"period":"6month","weight":-0.8982},{"period":"1year","weight":-0.9972},{"period":"ytd","weight":-0.9359}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.205941},{"month":5,"riseRate":0.25,"avgChangeRate":-0.137133},{"month":6,"riseRate":0.25,"avgChangeRate":-0.036058},{"month":7,"riseRate":0.25,"avgChangeRate":-0.051574},{"month":8,"riseRate":0.5,"avgChangeRate":-0.029706},{"month":9,"riseRate":0,"avgChangeRate":-0.272551},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction